ProRx LLC Initiates Class II Recall of Semaglutide Injection Due to Sterility Concerns, Marking Second Such Event
ProRx LLC has initiated a Class II recall of 2,649 vials of Semaglutide Injection (2.5mg/1mL) due to a lack of sterility assurance. This marks the second sterility-related recall for ProRx LLC in just over a year, raising significant concerns for procurement and regulatory teams regarding supply chain reliability and patient safety from compounded products.
FDA Mandates Class II Recall for ProRx LLC's Semaglutide Injection Over Sterility Concerns
On October 15, 2025, the U.S. Food and Drug Administration (FDA) initiated a Class II recall, D-0118-2026, for ProRx LLC's Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial. This action directly impacts 2,649 vials from Lot Prorx051525-5, distributed across Texas (TX) and Utah (UT). The primary reason for this recall is a critical 'lack of assurance of sterility,' which poses a significant risk to patient health, particularly for an injectable product intended for subcutaneous use. For procurement directors and supply chain VPs, this event necessitates an immediate review of inventory and distribution channels for this specific compounded Semaglutide product. The Class II classification indicates that exposure to the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, for a sterile injectable, any breach of sterility assurance is a severe concern, potentially leading to infections and adverse patient outcomes. Business development executives must consider the reputational damage and market disruption this recall creates, especially in the growing market for GLP-1 agonists like Semaglutide.
ProRx LLC's Exton Facility and Impact on Compounded Semaglutide Supply
The recalled Semaglutide Injection was manufactured by ProRx LLC at its facility located at 619 Jeffers Cir, Exton, PA 19341, United States. This facility, identified as ProRx — Exton, specializes in formulation, indicating its role in compounding pharmaceutical products. The product, bearing NDC: 84139-225-06, is a compounded version of Semaglutide, a molecule widely used for diabetes management and weight loss. The recall of 2,649 vials, specifically distributed to TX and UT, directly impacts healthcare providers and patients in these regions who rely on compounded alternatives. For regulatory affairs heads, this highlights the heightened scrutiny on compounding pharmacies, particularly concerning sterile preparations. The limited distribution pattern, while geographically contained, does not diminish the severity of the sterility breach. Procurement teams sourcing compounded injectables must recognize that issues at a single formulation facility like ProRx — Exton can lead to immediate supply disruptions, necessitating robust contingency plans and a thorough understanding of their suppliers' manufacturing processes and quality control measures.
Supply Chain Exposure and Market Implications for Compounded GLP-1 Agonists
The recall of ProRx LLC's Semaglutide Injection creates immediate supply chain exposure for healthcare providers and pharmacies in Texas and Utah. With 2,649 vials affected, any entity that has procured this specific lot (Prorx051525-5) must quarantine and return the product, leading to potential treatment interruptions for patients. For procurement directors, this event underscores the inherent risks associated with sourcing compounded medications, which often fill gaps when innovator drugs face shortages or are not commercially viable for specific patient needs. While specific downstream formulators or API suppliers are not detailed in the source, the incident serves as a critical reminder for all stakeholders in the compounded drug supply chain to enhance their vendor qualification processes. Regulatory affairs heads must advise their organizations on the increased regulatory focus on compounding pharmacies, especially those producing sterile injectables. Business development executives should note that such recalls can erode market confidence in compounded alternatives, potentially shifting demand back to innovator products or to compounding pharmacies with demonstrably superior quality systems, even if at a higher cost.
ProRx LLC's Recurring Sterility Issues: A Pattern of Compliance Risk
This Class II recall of Semaglutide Injection is not an isolated incident for ProRx LLC, signaling a concerning pattern of quality control deficiencies, particularly regarding sterility assurance. ChemLifeIntel's intelligence indicates that ProRx LLC faced a prior FDA-mandated nationwide recall on September 11, 2024, for its compounded Tirzepatide, also due to sterility concerns. This history of repeat sterility failures across different compounded GLP-1 agonist products (Semaglutide and Tirzepatide) from the same manufacturer, ProRx LLC, elevates the risk profile significantly. For regulatory affairs heads, this demonstrates a systemic issue within ProRx LLC's manufacturing processes at its Exton facility, suggesting that previous corrective actions may have been insufficient or improperly implemented. Procurement directors must view ProRx LLC as a high-risk supplier for sterile compounded products. The recurrence of such critical issues warrants a re-evaluation of all contracts and potential discontinuation of sourcing from ProRx LLC, given the persistent threat to patient safety and the operational disruptions caused by repeated recalls. This pattern could trigger more stringent FDA oversight, including potential import alerts if the company were to distribute internationally, or further enforcement actions.
Remediation Timeline and Enhanced FDA Scrutiny for ProRx LLC
The recall of ProRx LLC's Semaglutide Injection is currently 'Ongoing,' meaning the firm is actively working to remove the affected product from the market and address the underlying sterility issues. ProRx LLC is expected to conduct a thorough investigation into the root cause of the 'lack of assurance of sterility' and implement comprehensive corrective and preventive actions (CAPA). For regulatory affairs heads, monitoring the FDA's response and ProRx LLC's remediation plan will be crucial. The FDA will likely increase its scrutiny of the Exton facility, potentially leading to further inspections and, if deficiencies persist, more severe enforcement actions such as a Warning Letter, injunction, or even facility closure. Given the company's prior sterility recall for compounded Tirzepatide, the FDA will expect robust, systemic changes rather than superficial fixes. Procurement directors should anticipate prolonged uncertainty regarding ProRx LLC's ability to reliably supply sterile compounded products. This situation necessitates a proactive approach to identify and qualify alternative suppliers, as the timeline for ProRx LLC to regain full FDA confidence and ensure consistent sterility assurance could be extensive, impacting long-term supply stability.
Mitigating Supply Chain Risk: Strategies for Sourcing Compounded Injectables
In light of ProRx LLC's repeated sterility recalls, procurement directors and supply chain VPs must implement robust strategies to mitigate risks associated with sourcing compounded sterile injectables. First, conduct enhanced due diligence on all compounding pharmacy partners, focusing on their FDA inspection history, recall records, and quality management systems, particularly for sterile manufacturing. Demand transparency regarding their environmental monitoring, personnel training, and sterilization validation protocols. Second, diversify your supplier base for critical compounded products like Semaglutide. Relying on a single compounding pharmacy, especially one with a history of compliance issues, exposes your business to unacceptable supply disruptions and patient safety risks. Third, establish clear contractual terms that include stringent quality clauses, audit rights, and performance metrics related to regulatory compliance. While specific alternative suppliers for compounded Semaglutide are not named in this intelligence, the market for compounded GLP-1 agonists is dynamic. Proactively identify and qualify multiple reputable compounding pharmacies that demonstrate a strong track record of FDA compliance and robust sterility assurance programs to safeguard your supply chain and protect patient welfare.